Duodenal ulcer
Conditions
Interventions
Group 1:levamoprazole sodium enteric-coated tablets
Group 2:Pantoprazole enteric-coated tablets
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) aged 18 to 70 years old male and female; (2) meet the diagnostic criteria for duodenal ulcer; (3) duodenal ulcer was confirmed by gastroscopy in the first week, and Sakita and Miwa ulcer stage was A1 or A2. (4) the number of ulcers is no more than 2, and the maximum diameter is no more than 2.0 cm; (5) drugs for treating peptic ulcer (such as PPIs, h2-ras and gastric mucosa protectant) were not used within 1 week before enrollment; (6) agree to participate in this clinical trial and have signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) have a history of allergy to experimental drugs and their ingredients; (2) patients with cancerous ulcer, zhuo-ai syndrome, esophageal lesions (esophageal erosion, varicose veins or ulcers), gastric fundus stroma, gastric varicose veins, gastric MALT lymphoma or gastric ulcer; (3) history of gastric surgery: partial gastrectomy, gastroplasty, vagus nerve amputation (but patients who have had simple perforation repair for gastric ulcer or ulcer suture for hemostasis can be included); (4) severe complications, such as pyloric obstruction and endoscopic bleeding; (5) patients with other serious digestive tract diseases, such as crohn's disease, ulcerative colitis, etc.; (6) patients with severe liver and kidney diseases, or abnormal liver and kidney function examination (ALT and AST = 1.5 times the normal upper limit and SCr > normal upper limit); (7) severe heart and lung diseases, advanced tumors, blood and hematopoietic system diseases, or other serious or progressive systemic diseases; (8) inability or unwillingness to cooperate due to neurological or mental disorders; (9) suspected or true history of alcohol and drug abuse, or other conditions that, according to the researcher's judgment, have reduced the possibility of enrollment or complicated the enrollment; (10) women during pregnancy and lactation and patients with family planning for the next six months; (11) the investigator considers it inappropriate to participate in the clinical trial; (12) participated in other clinical trials three months before the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The healing rate of ulcer was observed under gastroscope; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total effective rate of clinical symptom relief;Major symptoms (upper abdominal pain, antacids) disappearance rate;Duration of major symptoms (upper abdominal pain, antacids); | — |
Countries
China
Contacts
Public ContactSide Liu
Nanfang Hospital, Southern Medical University
Outcome results
None listed